Last $20.90 USD
Change Today -0.88 / -4.04%
Volume 418.7K
FMI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Open
$21.88
Previous Close
$21.78
Day High
$22.19
Day Low
$20.85
52 Week High
03/19/14 - $45.00
52 Week Low
09/24/13 - $18.00
Market Cap
590.6M
Average Volume 10 Days
273.6K
EPS TTM
$-4.92
Shares Outstanding
28.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FOUNDATION MEDICINE INC (FMI)

foundation medicine inc (FMI) Related Bloomberg News

View More Bloomberg News

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. The company offers clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme, for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

186 Employees
Last Reported Date: 03/7/14
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $403.9K
Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $330.0K
Senior Vice President and General Counsel
Total Annual Compensation: $178.5K
Compensation as of Fiscal Year 2013.

foundation medicine inc (FMI) Key Developments

Foundation Medicine, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Earnings Guidance for 2014

Foundation Medicine, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. Foundation Medicine reported total revenue of $14.5 million in the second quarter of 2014, a 145% increase compared to $5.9 million in the second quarter of 2013 and a 27% increase compared to $11.5 million in the first quarter of 2014. Loss from operations was $13,763,000 against $10,026,000 for the same period of last year. Net loss applicable to common stockholders was $13,779,000 against $10,229,000 for the same period of last year. Net loss per basic and diluted share applicable to common stockholders was $0.49 against $3.34 for the same period of last year. For the six months, revenue was $25,951,000 against $11,120,000 for the same period of last year. Loss from operations was $25,904,000 against $17,147,000 for the same period of last year. Net loss applicable to common stockholders was $25,945,000 against $17,482,000 for the same period of last year. Net loss per basic and diluted share applicable to common stockholders was $0.93 against $5.92 for the same period of last year. The company confirmed its prior guidance for 2014, including: revenue to be in the range of $52 to $58 million.

Foundation Medicine, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM

Foundation Medicine, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Michael J. Pellini, Chief Executive Officer, President and Director.

Foundation Medicine, Inc. Appoints Lisa Ricciardi as Senior Vice President, Corporate and Business Development

Foundation Medicine, Inc. announced the appointment of life sciences executive Lisa Ricciardi to the newly created position of senior vice president, corporate and business development. In this role, Ms. Ricciardi will be responsible for overseeing the company's biopharmaceutical partnerships as well as corporate and business development activities across the company. Prior to joining the company, Ms. Ricciardi held numerous senior business development and marketing roles in pharmaceuticals, healthcare services, and finance. Ms. Ricciardi spent several years at Pfizer culminating in the role of senior vice president, licensing and development, where she led more than two dozen complex, multinational, multi-year deals across a host of disease areas, including oncology. Ms. Ricciardi was also a venture partner for Essex Woodlands Health Ventures, and served as senior vice president of U.S. and international business development in the healthcare services sector at Medco Health Solutions. Most recently, Ms. Ricciardi served as a consultant to the specialty pharmacy division of DaVita, a full-service pharmacy specializing in renal care. Ms. Ricciardi is currently a member of the Board of Directors of United Drug Group, PLC in Dublin, Ireland, and a director with Chimerix in Durham, North Carolina.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $20.90 USD -0.88

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeoGenomics Inc $5.57 USD +0.12
Response Genetics Inc $0.78 USD +0.0401
Rosetta Genomics Ltd $3.62 USD -0.20
Sequenom Inc $3.14 USD -0.11
Signal Genetics Inc $4.50 USD -0.19
View Industry Companies
 

Industry Analysis

FMI

Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit www.foundationmedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.